Blood pressure

Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia

Retrieved on: 
Monday, March 11, 2024

CHATHAM, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional efficacy data from RESILIENT, the second positive Phase 3 study evaluating Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, at the 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium, March 7-8, 2024.

Key Points: 
  • We now report that the effect sizes of the five continuous key secondary outcomes measures ranged from 0.3 to 0.5.
  • The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients vs placebo-treated patients with a p=0.001 and effect size of 0.31.
  • RELIEF, the first Phase 3 trial of Tonmya 5.6 mg in fibromyalgia, was completed in December 2020.
  • We also believe the favorable tolerability and side effect profiles will be important to patients and doctors managing this debilitating condition on a long-term basis.”

Brain Canada Celebrates Brain Health Awareness Month with Boost your Brain Awareness Campaign

Retrieved on: 
Monday, March 11, 2024

MONTREAL, March 11, 2024 (GLOBE NEWSWIRE) --  Brain Canada is marking this year’s Brain Health Awareness Month by launching the Boost your Brain Awareness campaign to draw attention to how the body’s most critical organ works in health and illness.

Key Points: 
  • Brain Canada marks 2024 Brain Health Awareness Month with a Boost your Brain Awareness Campaign to better understand our most critical organ in health and illness.
  • MONTREAL, March 11, 2024 (GLOBE NEWSWIRE) -- Brain Canada is marking this year’s Brain Health Awareness Month by launching the Boost your Brain Awareness campaign to draw attention to how the body’s most critical organ works in health and illness.
  • This month, Brain Canada will be highlighting different ways to boost our brain awareness.
  • “Brain Health Awareness Month is an opportunity to remind people in Canada of the critical role research plays in maintaining and improving our collective brain health,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Retrieved on: 
Wednesday, March 6, 2024

These data demonstrate the favorable impact of AVIM therapy compared to standard right ventricular (RV) pacing on systolic blood pressure and overall cardiac function when delivered using both conduction system andstandard pacing lead locations.

Key Points: 
  • These data demonstrate the favorable impact of AVIM therapy compared to standard right ventricular (RV) pacing on systolic blood pressure and overall cardiac function when delivered using both conduction system andstandard pacing lead locations.
  • The PV loop study was conducted at Na Homolce Hospital in Prague by Prof. Petr Neužil, M.D.
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • “Well-conducted invasive PV loop studies are a robust way to evaluate the impact of a novel therapy like AVIM on hemodymanics and overall cardiac function.

LiveCare Inc's (OTCMKTS: LVCE) Blood Pressure Cuff Sets New Standards in Healthcare, Fueling Remarkable Growth and Patient Adoption

Retrieved on: 
Tuesday, March 5, 2024

The introduction of the Blood Pressure Cuff by LiveCare Inc has opened a vast new market, catering to the needs of more than 122 million people with high blood pressure, according to a 2023 report from the American Heart Association.

Key Points: 
  • The introduction of the Blood Pressure Cuff by LiveCare Inc has opened a vast new market, catering to the needs of more than 122 million people with high blood pressure, according to a 2023 report from the American Heart Association.
  • Recognizing the challenges and discomfort associated with traditional blood glucose monitoring methods, LiveCare Inc has ingeniously addressed a critical healthcare gap.
  • “The success of our Blood Pressure Cuff is a testament to our commitment to our patients.
  • The success of the Blood Pressure Cuff is a testament to LiveCare Inc's commitment to advancing healthcare through technology connected to its Health Center supporting 24/7 live human interaction.

REMSleep Holdings Shareholder Update

Retrieved on: 
Monday, March 4, 2024

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points: 
  • CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
  • We have had numerous inquiries asking for REMSleep regulatory status update.
  • REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
  • REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

LiveCare Inc.(OTCMKTS: LVCE) Enters Hypertension Market, Enhancing Healthcare Monitoring for U.S. Adults

Retrieved on: 
Wednesday, February 28, 2024

This device represents a significant step forward in combating high blood pressure, a prevalent condition affecting roughly one-third of adults in the United States.

Key Points: 
  • This device represents a significant step forward in combating high blood pressure, a prevalent condition affecting roughly one-third of adults in the United States.
  • A distinguishing feature of the LiveCare Health approach is the real-time transmission of device readings to the health center.
  • The demand for blood pressure monitoring devices is substantial and expanding, fueled by growing recognition of the critical role of early hypertension detection and management.
  • With an estimated 75 million American adults diagnosed with high blood pressure, the potential impact of LiveCare Inc.'s new device is considerable.

Third Pole Therapeutics Announces Successful Completion of Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System

Retrieved on: 
Tuesday, February 27, 2024

This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).

Key Points: 
  • This study evaluated eNOfit™, a miniaturized, portable inhaled nitric oxide (iNO) generator and delivery system for the ambulatory treatment of patients suffering from pulmonary hypertension (PH) associated with Interstitial Lung Disease (ILD).
  • “The successful completion of our EFS which validated the safe and practical use of our eNOfit™ system, enables us to confidently move into larger randomized placebo-controlled safety and efficacy studies.
  • Importantly, this value creating milestone will trigger the final funding of Third Pole’s Series B investment round.” said Bill Athenson, CEO of Third Pole.
  • Inhaled nitric oxide relaxes smooth muscle within the pulmonary vasculature, increasing the diameter of pulmonary arteries and decreasing their resistance to blood flow.

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

Retrieved on: 
Monday, February 26, 2024

“These new long-term follow up data demonstrate AVIM therapy’s ability to drive a substantial and sustained reduction in 24-hour ambulatory systolic blood pressure, the gold standard, and most accurate measure of hypertension.

Key Points: 
  • “These new long-term follow up data demonstrate AVIM therapy’s ability to drive a substantial and sustained reduction in 24-hour ambulatory systolic blood pressure, the gold standard, and most accurate measure of hypertension.
  • Each patient’s aSBP was measured an average of 3.6 (±0.6) years following original initiation of AVIM therapy.
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • Orchestra BioMed and Medtronic plc (NYSE: MDT) (“Medtronic”) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Retrieved on: 
Tuesday, March 5, 2024

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.

Key Points: 
  • Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
  • “We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
  • “These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
  • The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.

Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Monday, March 4, 2024

Key highlights of Better Therapeutics’ participation at ATTD include:

Key Points: 
  • Key highlights of Better Therapeutics’ participation at ATTD include:
    The late-breaking abstract findings further validate the use of AspyreRx ™ as a safe and effective treatment for patients with type 2 diabetes (T2D).
  • Abstract Title: Randomized, Controlled Trial Of A Novel Digital Therapeutic In Patients With Type 2 Diabetes: BT-001 Pivotal Trial 180 Day Outcomes
    Abstracts will be published in the peer-reviewed Journal of Diabetes Technology & Therapeutics.
  • Additionally, Better Therapeutics will host a sponsored industry symposium on Saturday, March 09, 2024, at 8:30 a.m. local time (CET).
  • Attendees will have the opportunity to experience AspyreRx firsthand and learn more about its clinical benefits at the Better Therapeutics exhibition booth.